We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$173M
AUM Growth
+$11M
Cap. Flow
+$39.8M
Cap. Flow %
23.02%
Top 10 Hldgs %
48.18%
Holding
76
New
24
Increased
16
Reduced
11
Closed
16

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.2M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$5.3M
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$4.37M
4
IMMU
Immunomedics Inc
IMMU
+$4.37M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$4.03M

Top Sells

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$8.74M
2
FOLD
Amicus Therapeutics
FOLD
+$5.81M
3
AVID
Avid Technology Inc
AVID
+$3.07M
4
LMAT icon
LeMaitre Vascular
LMAT
+$3.02M
5
TLGT
Teligent, Inc
TLGT
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 74.16%
2 Consumer Discretionary 2.56%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCGN icon
51
Ocugen
OCGN
$424M
$491K 0.28%
2,054
– –
ABEO icon
52
Abeona Therapeutics
ABEO
$364M
$451K 0.26%
+4,454
New +$591K
CEMP
53
DELISTED
Cempra, Inc.
CEMP
$418K 0.24%
15,000
– –
VIVS
54
PUT
VivoSim Labs
VIVS
$1.17M
$322K 0.19%
+500
New +$380K
ZSAN
55
DELISTED
Zosano Pharma Corporation
ZSAN
$292K 0.17%
105
-20
-16% -$112K
ARWR icon
56
PUT
Arrowhead Research
ARWR
$12.1B
$288K 0.17%
+50,000
New +$314K
KIN
57
DELISTED
Kindred Biosciences, Inc.
KIN
$260K 0.15%
50,000
– –
AXDX
58
PUT
DELISTED
Accelerate Diagnostics
AXDX
$243K 0.14%
+1,500
New +$325K
ADAP
59
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-30,000
Closed -$550K
COLL icon
60
Collegium Pharmaceutical
COLL
$1.15B
– –
-130,000
Closed -$2.32M
HUM icon
61
Humana
HUM
$45B
– –
-6,000
Closed -$1.15M
LMAT icon
62
LeMaitre Vascular
LMAT
$2.37B
– –
-250,000
Closed -$3.02M
NUWE icon
63
PUT
Nuwellis
NUWE
$587K
– –
0
– -$207K
SMLR
64
DELISTED
Semler Scientific
SMLR
– –
-80,935
Closed -$267K
ARAV
65
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-8,333
Closed -$761K
AVID
66
DELISTED
Avid Technology Inc
AVID
– –
-230,000
Closed -$3.07M
OTIC
67
DELISTED
Otonomy, Inc.
OTIC
– –
-53,400
Closed -$1.23M
TLGT
68
DELISTED
Teligent, Inc
TLGT
– –
-46,294
Closed -$2.92M
EGOV
69
DELISTED
NIC Inc
EGOV
– –
-70,000
Closed -$1.28M
FOMX
70
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-30,000
Closed -$308K
CASC
71
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-111,667
Closed -$2.51M
MOLG
72
DELISTED
MOL GLOBAL INC SPONSORED ADR
MOLG
– –
-147,912
Closed -$226K
AWAY
73
DELISTED
HOMEAWAY INC COM
AWAY
– –
-25,000
Closed -$778K
CEMI
74
DELISTED
Chembio diagnostics, Inc.
CEMI
– –
-130,000
Closed -$638K
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2015 Portfolio in Review

As of Q3 2015, Acuta Capital Partners held 76 positions worth $173M, up 6.8% from $162M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Acuta Capital Partners deployed $39.8M of net new capital in Q3 2015, opening 24 new positions and adding to 16 existing holdings. Its largest new stake was Exelixis: 1,880,004 shares worth $10.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 81% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Applied Genetic Technologies Corporation, an estimated $8.74M trimmed.

  • Acuta Capital Partners's largest Q3 2015 buy was Exelixis: 1,880,004 shares worth $10.5M.
  • Acuta Capital Partners added most to NeuroDerm Ltd. Ordinary Shares in Q3 2015, an estimated $4.03M increase.
  • Acuta Capital Partners's biggest Q3 2015 reduction was Applied Genetic Technologies Corporation, cutting an estimated $8.74M.
  • Acuta Capital Partners fully exited Avid Technology Inc in Q3 2015, selling an estimated $3.07M.
  • Acuta Capital Partners's ten largest holdings make up 48% of its $173M portfolio in Q3 2015.
  • Acuta Capital Partners opened 24 new positions and closed 16 in Q3 2015.
  • Acuta Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $173M.

Based on Acuta Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.